Aerie Pharmaceuticals (NASDAQ:AERI) Announces Earnings Results

Aerie Pharmaceuticals (NASDAQ:AERI – Get Rating) issued its quarterly earnings results on Thursday. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.20, Fidelity Earnings reports. During the same quarter last year, the business posted ($0.67) EPS.

Aerie Pharmaceuticals Price Performance

Aerie Pharmaceuticals stock traded up $1.54 during midday trading on Friday, hitting $8.91. 1,513,809 shares of the stock were exchanged, compared to its average volume of 421,767. Aerie Pharmaceuticals has a fifty-two week low of $4.81 and a fifty-two week high of $17.21. The stock’s 50-day simple moving average is $7.16 and its 200 day simple moving average is $7.44.

Institutional Investors Weigh In On Aerie Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Rice Hall James & Associates LLC lifted its stake in Aerie Pharmaceuticals by 39.5% in the first quarter. Rice Hall James & Associates LLC now owns 1,678,609 shares of the company’s stock worth $15,275,000 after acquiring an additional 475,017 shares during the last quarter. PDT Partners LLC increased its holdings in shares of Aerie Pharmaceuticals by 298.1% in the 1st quarter. PDT Partners LLC now owns 160,915 shares of the company’s stock valued at $1,464,000 after acquiring an additional 120,498 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Aerie Pharmaceuticals by 29.6% in the 1st quarter. Renaissance Technologies LLC now owns 498,210 shares of the company’s stock valued at $4,534,000 after acquiring an additional 113,900 shares during the period. Alyeska Investment Group L.P. acquired a new position in shares of Aerie Pharmaceuticals in the 1st quarter valued at $910,000. Finally, Panagora Asset Management Inc. acquired a new position in Aerie Pharmaceuticals in the 1st quarter valued at $446,000.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded shares of Aerie Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, June 28th.

Aerie Pharmaceuticals Company Profile

(Get Rating)

Aerie Pharmaceuticals, Inc, a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension.